Trial reportJCI insight2017
Early molecular correlates of adverse events following yellow fever vaccination.
Trial report in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07527247 (Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity
Who cites it
17 citing papers in PubMed.
- Trial
- Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.Nature microbiology · 2025Trial
- Observational
- Review
- Development of a personalized digital biomarker of vaccine-associated reactogenicity using wearable sensors and digital twin technology.Communications medicine · 2025Article
- Electron transport chain capacity expands yellow fever vaccine immunogenicity.EMBO molecular medicine · 2024Article
- Feasibility of Using a Type I IFN-Based Non-Animal Approach to Predict Vaccine Efficacy and Safety Profiles.Vaccines · 2024Review
- Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.Journal of virology · 2024Article
- Towards personalized vaccines.Frontiers in immunology · 2024Review
- Q fever immunology: the quest for a safe and effective vaccine.NPJ vaccines · 2023Review
- STAGEs: A web-based tool that integrates data visualization and pathway enrichment analysis for gene expression studies.Scientific reports · 2023Article
- Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Article
- Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.PLoS pathogens · 2021Article
- Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection.EBioMedicine · 2020Article
- Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection.Nature medicine · 2019Article
- The how's and what's of vaccine reactogenicity.NPJ vaccines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The innate immune response shapes the development of adaptive immunity following infections and vaccination. However, it can also induce symptoms such as fever and myalgia, leading to the possibility that the molecular basis of immunogenicity and reactogenicity of vaccination are inseparably linked. To test this possibility, we used the yellow fever live-attenuated vaccine (YFLAV) as a model to study the molecular correlates of reactogenicity or adverse events (AEs). We analyzed the outcome of 68 adults who completed a YFLAV clinical trial, of which 43 (63.2%) reported systemic AEs. Through whole-genome profiling of blood collected before and after YFLAV dosing, we observed that activation of innate immune genes at day 1, but not day 3 after vaccination, was directly correlated with AEs. These findings contrast with the gene expression profile at day 3 that we and others have previously shown to be correlated with immunogenicity. We conclude that although the innate immune response is a double-edged sword, its expression that induces AEs is temporally distinct from that which engenders robust immunity. The use of genomic profiling thus provides molecular insights into the biology of AEs that potentially forms a basis for the development of safer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.